Pfizer Chantix Class Action Lawsuit
A lawsuit said Pfizer sold Chantix contaminated with a probable human carcinogen while misrepresenting its manufacturing standards. Pfizer denies wrongdoing.
What happens next with the Pfizer Chantix settlement
The claim deadline passed on September 12, 2026. New claims for this settlement are no longer being accepted.
The court held its approval hearing on October 13, 2026. That was the final approval hearing, where a judge decides whether to approve the settlement. Nothing is paid out until that approval is final.
Payments come after approval, and after any appeals. Anyone who objected to the settlement can ask a higher court to look at it again — an appeal — and that has to finish first. Eligible payments are sent once approval is final, and the stretch from a claim deadline to money in hand often runs a year or more. It varies from one settlement to the next.
Filed this claim with Chimo? The status of your claim is on the claims page in your account.
Settlements you can still claim in October 2026
Generic Drug Makers (State AGs)
$59
Kroger
$52
Generic Drugs
$10
Pfizer Chantix Class Action Lawsuit
Chantix buyers and health plans sued Pfizer Inc. over its smoking-cessation drug Chantix (varenicline), saying that Pfizer failed to follow current good manufacturing practices and that Chantix pills became contaminated with N-nitroso-varenicline, a nitrosamine impurity described in court filings as a genotoxic, probable human carcinogen. Pfizer recalled Chantix lots in the United States in 2021, and in December 2022 the suits were centralized into a multidistrict litigation in the U.S. District Court for the Southern District of New York before Judge Katherine Polk Failla (case number 22-MD-3050). The consolidated complaint was filed on May 5, 2023.
The Chantix class action case centered on claims that Pfizer misrepresented its adherence to good manufacturing practices while selling a premium-priced branded drug. The consolidated complaint included claims for breach of warranty, fraud, negligent misrepresentation, violations of state consumer protection laws, and unjust enrichment, though the court later narrowed the case to the consumer protection claims and certain unjust enrichment and negligent misrepresentation claims.
Court-appointed class counsel from Honik LLC, Levin Sedran & Berman LLP, and Scott+Scott Attorneys at Law LLP reviewed more than 250,000 documents totaling roughly 2.11 million pages before reaching the settlement. Pfizer denies any wrongdoing, and the court has not decided who is right; Pfizer settled to avoid the cost and uncertainty of continued litigation over the Chantix legal claims.
Pfizer Chantix Class Action Settlement - $44,000,000
Pfizer has agreed to pay $44,000,000 to resolve the Chantix class action settlement, and the court granted preliminary approval on June 1, 2026. The settlement fund is non-reversionary, meaning none of the $44 million goes back to Pfizer. The settlement covers everyone who paid any amount of money for retail purchases of Chantix in the United States and its territories between September 29, 2015, and September 17, 2021 — both individual consumers and third-party payors such as insurers.
After attorneys' fees, litigation expenses, administration costs, and service awards are deducted, up to 20 percent of the available settlement fund is set aside for individual consumers, with the remainder going to third-party payors. That split reflects class counsel's best estimate of how much of every Chantix purchase was paid by patients versus their insurers.
Chantix settlement eligibility did not require any receipts or paperwork up front, and claims could be submitted online. The court's claim deadline was September 14, 2026 (the deadline to file with Chimo was September 12, 2026), and new claims can no longer be filed. A final approval hearing was scheduled for October 13, 2026.
Claims closed: September 12, 2026
Chantix Class Action Payout: Pro Rata Share, Up to Amount Paid
The settlement gives each consumer with an approved claim a pro rata share of the consumer portion of the fund, based on the total out-of-pocket amount they paid for Chantix — copays, coinsurance, and deductibles all count. No one's payment can exceed what they actually spent, so the amount per person varies: someone who paid a handful of $25 copays is eligible for less than someone who paid hundreds of dollars cash for the branded drug.
How much an eligible claimant receives depends on how much they paid and how many people filed. If money is left over after the first distribution, it is to be redistributed to claimants who claimed their payments rather than reverting to Pfizer.
Payments to eligible claimants are sent digitally by email by default, unless the claimant chose another payment method on the claim form. Payments are made only after final approval and any appeals; a final approval hearing was scheduled for October 13, 2026. Questions about a payment can go to the settlement administrator at 1-877-354-3912.
Chantix Class Action Eligibility
People qualified for the Chantix class action settlement if they paid any amount of money for retail purchases of Chantix in the United States or its territories between September 29, 2015, and September 17, 2021. Insurance users qualified too — what mattered was that they personally paid something out of pocket, whether that was a copay, coinsurance, a deductible, or the full cash price.
A few groups are excluded: officers, directors, managers, and employees of Pfizer; government agencies and governmental actors, including state attorney general offices; anyone whose only Chantix purchases fell outside the September 29, 2015, to September 17, 2021, window; anyone who bought Chantix for resale; and anyone who previously opted out of this case. Notably, only branded Chantix counts — purchases of generic varenicline are not covered.
Chantix class action claimants did not need receipts to file. The claim form asked how many prescriptions they purchased, how much they spent out of pocket in total, and whether insurance covered part of the cost.
FAQ
It is a nitrosamine impurity found in Chantix pills, described in court filings as a genotoxic, probable human carcinogen. Its discovery led Pfizer to halt distribution and recall Chantix lots in 2021.
No. Claimants just reported how many prescriptions they bought and their total out-of-pocket cost. The settlement administrator may later request backup like a pharmacy record, an insurance explanation of benefits, or prescription records.
No. Only retail purchases of brand-name Chantix, made by Pfizer, are covered. Generic varenicline is not part of this settlement; according to the complaint, the FDA approved generic versions after Pfizer's 2021 recalls.
Yes. Copays, coinsurance, and deductibles all count as out-of-pocket spending. The claim form asked for the claimant's insurer's name and policy number if insurance covered part of their purchases.
The rest goes to third-party payors like health plans, which typically paid the bulk of each prescription's price. The 20% cap reflects class counsel's estimate of the share consumers actually paid at the register.
Payments are sent digitally to the claimant's email address by default. Claimants could affirmatively choose an alternative payment method when they filed, so keep your email and phone number current with the administrator.
Nothing goes back to Pfizer — the $44 million fund is non-reversionary. Leftover funds after the first distribution are redistributed pro rata to class members who claimed their payments.
Class counsel could request up to one-third of the fund plus expenses, subject to court approval. Named consumer plaintiffs sought $5,000 service awards each; third-party payor plaintiffs sought $15,000 each.
No. Pfizer denies any wrongdoing and maintains it did nothing unlawful. It settled to avoid the uncertainty and expense of continued litigation after years of discovery in the multidistrict case.
No. Each consumer's recovery is capped at their documented out-of-pocket spending. If total claims exceed the consumer allocation, every payment is reduced proportionally based on dollars paid.
Sources
These are the court's own records for this case. They are hosted here unchanged, so you can check anything on this page against the documents themselves.
- Consolidated Master Class Action Complaint (PDF) Complaint · Filed May 5, 2023 · U.S. District Court for the Southern District of New York · Case 22-MD-3050 (KPF)
The full case file is on the court docket: view the docket.